Skip to main content

Hancock Jaffe Laboratories, Inc. (HJLI)

NASDAQ: HJLI · IEX Real-Time Price · USD
9.63 0.64 (7.12%)
Sep 21, 2021 3:16 PM EDT - Market open
Market Cap85.10M
Revenue (ttm)n/a
Net Income (ttm)-12.11M
Shares Out8.51M
EPS (ttm)-2.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume153,948
Open9.09
Previous Close8.99
Day's Range9.08 - 9.63
52-Week Range4.99 - 17.68
Beta1.54
AnalystsStrong Buy
Price Target26.00 (+170.0%)
Est. Earnings DateNov 15, 2021

About HJLI

Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf...

IndustryHealth Care Equipment & Supplies
Founded1987
Employees19
Stock ExchangeNASDAQ
Ticker SymbolHJLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for HJLI stock is "Strong Buy" and the 12-month stock price forecast is 26.00.

Price Target
$26.00
(169.99% upside)
Analyst Consensus: Strong Buy

News

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaff...

6 days ago - Accesswire

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered...

2 weeks ago - Accesswire

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.

1 month ago - Benzinga

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had ...

1 month ago - Accesswire

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

The FDA has granted Breakthrough Device Designation status to  Hancock Jaffe Laboratories Inc's (NASDAQ:HJLI) VenoValve, the Company's lead product, currently set to begin its U.S. pivotal trial.  The V...

1 month ago - Benzinga

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE ...

1 month ago - Accesswire

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical device...

2 months ago - Accesswire

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Char...

IRVINE, CA / ACCESSWIRE /  April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernan...

4 months ago - Accesswire

First U.S. Patent Issues on Hancock Jaffe VenoValve

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States ...

5 months ago - Accesswire

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and ...

5 months ago - Accesswire

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a...

6 months ago - Accesswire

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / January 12, 2021 /  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices tha...

8 months ago - Accesswire

Hancock Jaffe Announces Executive Promotions

IRVINE, CA / ACCESSWIRE / December 30, 2020  / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Ala...

8 months ago - Accesswire

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Company Regains Compliance with NASDAQ Minimum Bid Requirement IRVINE, CA / ACCESSWIRE / December 21, 2020  / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore ...

9 months ago - Accesswire